Feb 16, 2023 | Press Releases
A positive difference in physical function in responders versus non-responders was noted The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone CULVER CITY, Calif., February 16, 2023 — ImmunityBio,...
Feb 15, 2023 | Press Releases
CULVER CITY, Calif., February 15, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into...
Jan 19, 2023 | Press Releases
Positive findings in third line and greater metastatic pancreatic cancer patients (N=83) with doubled median overall survival (OS) versus historical OS Median overall survival of 5.8 months and 61% of patients (51/83) exhibited disease control All treatments in an...
Dec 12, 2022 | Press Releases
Financing transactions include approximately $50 million of equity financing from a single institutional investor, $50 million of debt financing from Nant Capital, LLC, and conversion of approximately $56.6 million of debt held by NantWorks LLC into ImmunityBio...
Nov 17, 2022 | Press Releases
CULVER CITY, Calif., November 17, 2022 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City,...
Nov 10, 2022 | Press Releases
Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median duration of response of 26.6 months, a 53% CR rate at 24 months and a safety profile comparable to BCG alone This novel IL-15 superagonist N-803 –...
